National Commission on Digestive Diseases
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

National Commission on Digestive Diseases

  • 425 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
425
On Slideshare
425
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • INSTRUCTIONS: Outline the major points to be included in the “background and introduction” section of your chapter. In general, this section should include an overview of the area, importance, common conditions and their disease burden, epidemiology, current understanding of pathogenesis and natural history, and current means of control, cure, and/or prevention. Insert additional slides using the same format as needed.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Outline the scientific research areas or diseases/disorders that fall within the scope of your chapter. For example, the chapter on “Functional Gastrointestinal Disorders and Motility Disorders” will include: irritable bowel syndrome, gastroparesis,….. Insert additional slides using the same format as needed.
  • INSTRUCTIONS: Outline the scientific research areas or diseases/disorders that fall within the scope of your chapter. For example, the chapter on “Functional Gastrointestinal Disorders and Motility Disorders” will include: irritable bowel syndrome, gastroparesis,….. Insert additional slides using the same format as needed.
  • INSTRUCTIONS: Outline the scientific research areas or diseases/disorders that fall within the scope of your chapter. For example, the chapter on “Functional Gastrointestinal Disorders and Motility Disorders” will include: irritable bowel syndrome, gastroparesis,….. Insert additional slides using the same format as needed.
  • INSTRUCTIONS: Outline the scientific research areas or diseases/disorders that fall within the scope of your chapter. For example, the chapter on “Functional Gastrointestinal Disorders and Motility Disorders” will include: irritable bowel syndrome, gastroparesis,….. Insert additional slides using the same format as needed.
  • INSTRUCTIONS: Outline the scientific research areas or diseases/disorders that fall within the scope of your chapter. For example, the chapter on “Functional Gastrointestinal Disorders and Motility Disorders” will include: irritable bowel syndrome, gastroparesis,….. Insert additional slides using the same format as needed.
  • INSTRUCTIONS: Outline the scientific research areas or diseases/disorders that fall within the scope of your chapter. For example, the chapter on “Functional Gastrointestinal Disorders and Motility Disorders” will include: irritable bowel syndrome, gastroparesis,….. Insert additional slides using the same format as needed.
  • INSTRUCTIONS: Outline the scientific research areas or diseases/disorders that fall within the scope of your chapter. For example, the chapter on “Functional Gastrointestinal Disorders and Motility Disorders” will include: irritable bowel syndrome, gastroparesis,….. Insert additional slides using the same format as needed.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.
  • INSTRUCTIONS: Comment on any aspect(s) of the nomination, recruitment, conference call, or chapter preparation process that has presented challenges or that has aided the process to date, as well as any future anticipated challenges.

Transcript

  • 1. National Commission on Digestive Diseases Chapter 8: Diseases of the Stomach and Small Intestine Chair: Eugene B. Chang Vice-Chair: Maurice Cerulli
  • 2. Background and Introduction Gastric and Small Bowel Disorders
    • Overview: Three major groupings:
      • Acid/peptic disorders
      • Diarrheal diseases, Malabsorption, maldigestion
      • Celiac disease and others (including pediatric disorders)
  • 3. Research Goal 1 : improve treatment of H. pylori acid-peptic diseases, OBJECTIVES
    • Profile the microbial, molecular, cellular and epidemiological features of H. pylori induced gastric carcinogenesis and PUD
      • Identify diagnostic, prognostic, predictive, preventive and therapeutic targets
    • Define relationship between HP & GERD
      • Assess prolonged proton-pump inhibitor use
    • Develop noninvasive tests for HP induced premalignant lesions
    • Develop prevention strategies for cancers
  • 4. Research Goal 2 : Reduce and prevent NSAID peptic diseases
    • Define pathogenic mechanisms of NSAID induced injury
    • Population based screening & pharmacogenomic approaches to identify at risk pts
    • Educate patient & MDs regarding risk factors & improve adherence to appropriate strategies to decrease NSAID GI complications
  • 5. Research Goal 2 : NSAIDs (continued)
    • Determine long term risk for chronic NSAID usage & PPI therapy, including risk of neoplasm
    • Design anti-inflammatory agents of comparable or higher efficacy to traditional NSAIDs without GI side effects and cardiovascular toxicity
  • 6. Research Goal 5
    • Determine the genetic, molecular, and integrated physiological bases of intestinal water, nutrient and electrolyte transport
  • 7. Research Goal 6
    • Improve treatment, prevention, and diagnosis of malabsorptive and diarrheal diseases
  • 8. Research Goal 6: Objectives
    • Determine the causes of chronic diarrheal diseases in 40% of pts in which no specific cause is identified (some will be due to polymorphisms and/or mutations in intestinal transporters).
    • Develop preventative measures to limit the incidence of acute diarrheal diseases. Evaluate the role of non-hydrolyzable starch based ORS in treatment of acute diarrhea in adults and children in developing countries and in the US
  • 9. Research Goal 6: Objectives (continued)
    • Develop clinically useful imaging & diagnostic techniques to examine digestive processes & abnormalities in diarrheal & malabsorptive diseases
    • Test new anti-Cl secretory and pro-Na absorptive drugs in animal models of acute diarrheal diseases. Conduct clinical trials for acute diarrhea
    • Develop gene therapy targeting intestinal epithelial cells and pharmacologic agents capable of blocking or augmenting pathways that control intestinal gene expression as part of future treatment strategies for chronic diarrheal and malabsorptive/maldigestive diseases
  • 10. Research Goal 7
    • Understand pathogenic mechanism of celiac disease and related autoimmune diseases
  • 11. Research Goal 7: Objectives
    • Define the early innate events and the interplay between innate and adaptive immunity in celiac disease pathogenesis
    • Elucidate the events leading to transglutaminase activation and define its role in celiac disease pathophysiology both as an autoantigen and as a modifier or toxic gluten peptides
    • Define mechanisms and events that link the generation of large gluten peptides and the ultimate development of pathogenic T cell populations
  • 12. Research Goal 7: Objectives (continued)
    • Define the role of antibodies and immune complexes in celiac disease
    • Define patterns in intestinal microbiome relevant to celiac disease and autoimmune/allergic disorders of the bowel
    • Define signaling pathway (eg protease, enteric toxins, cytokines) that are involved in the regulation of intestinal permeability under physiological and pathophysiological conditions
    • Distinguish between the effects of IL-23 and IL-12 in the pathogenesis of chronic inflammation
  • 13. Research Goal 8
    • Improve screening, diagnosis, prevention, and treatment of celiac disease and of autoimmune and allergic disorders of the bowel. Characterize and define the mechanism underlying the association of celiac disease with autoimmune and neurological diseases
  • 14. Research Goal 8 Objectives
    • Develop a more complete understanding of the pathogenesis of celiac disease, including the role of immune, epithelial, microbiological, environmental, and host factors as well as its relationship to other autoimmune diseases
    • Identify novel biomarkers, including additional genetic risk factors, to predict the development of autoimmune disease in high risk patients and to determine severity of illness and response to treatment
  • 15. Research Goal 8 Objectives (continued)
    • Identify environmental triggers of celiac disease
    • Identify new, non-invasive methods to diagnose celiac disease
    • Develop non-dietary methods to treat celiac disease
  • 16. Research Goal 9
    • Understand the pathogenesis of NEC and the unique susceptibility of the preterm infant, including genetic susceptibility , microbiome and immune/inflammatory processes
  • 17. Research Goal 11
    • Determine the genetic bases, mechanism, natural history, clinical phenotypes of EGIDS and identify/develop novel therapeutic compounds
  • 18. Research Goal 11 Objectives
    • Define the genetic bases, epidemiology and natural history of EGIDS
    • Define clinical phenotypes of EGIDS (e.g. allergic, non-allergic, or autoimmune) and develop novel animal models and reagents to study eosinophilic gastrointestinal inflammation
    • Define cellular & molecular pathways that regulate eosinophil-dependent tissue remodeling
  • 19. Research Goal 11 Objectives (continued)
    • Identify and develop novel agents for treatment of EGIDS such as anti-IL-5 antibody, anti-CCR3 receptor antibody, and imatimib
  • 20. Major Challenges to Achieve Goals
    • Animal models
    • Clinical research collaboration
    • Central research resources
    • Physician communication and education
    • Innovative technologies
    • Drug development
  • 21. Major Challenges to Achieve Goals
    • Animal models
    • Experimental models that replicate human disease include H. pylori-induced gastric cancer and ZES, intestinal transport, malabsorption & maldigestion, celiac disease, autoimmune & allergic disease of bowel & NEC
    • Animal models to study infection, morphologic interpretation of lesions, imaging technology, basic cellular processes such as endocytosis, migration & ion transport in intestine and drug testing
    • Related resources
      • Improved organ cultures
      • Organotypic culture technologies
      • H. pylori strain repositories
  • 22. Major Challenges to Achieve Goals
    • Clinical Research Collaboration
    • Multicenter, systems biology based consortia or networks of healthcare professionals to share materials & information and increase statistical power
    • Interdisciplinary, population based, endoscopic, multi-institutional studies to identify HP infected populations at greatest risk for gastric cancer and to determine the prevalence and natural history of pre-malignant lesions
    • Multicenter networks to coordinate research and management of diseases that include rare gastric tumors, ZES, dyspepsia, chronic diarrheal & malabsorptive diseases, NEC, celiac disease, and eosinophilic gastroenteritis
    • Small conferences for clinical & scientific interactions that could spark innovative approaches
  • 23. Major Challenges to Achieve Goals
    • Clinical Research Resources
    • Centralized resources, such as databases, patient registries & biosample repositories
    • Databases with an emphasis on enrollment of minority gastric cancer patients and specimen & tissue banks
    • Large scale biology approaches to identify protein-protein interactions, pH & Ca homeostasis during digestion and in diarrheal diseases in Na absorptive, Cl secretory & enteric endocrine cells
    • Repositories of clinical data & samples from celiac disease, eosinophilic gastroenteritis, & autoimmune pts or such high incidence families
  • 24. Major Challenges to Achieve Goals
    • Physician Communication & Education
    • Small conferences to promote interactions between adult & pediatric clinicians to define the natural history of these diseases
    • Programs to determine cause of poor adherence to guidelines, make appropriate recommendations, develop mechanisms to disseminate recommendations, assess whether recommendations are being followed, & assess alterations to outcomes (quality of care) for acid-peptic disease
    • Educational campaign to increase awareness of celiac disease among health care professionals
  • 25. Major Challenges to Achieve Goals
    • Innovative Technologies
    • Experimental tools & models to study intestinal epithelial physiology & diseases, including diarrhea, malabsorption, development, inflammation & pediatric diseases
    • Infrastructure to develop proteomics approaches to the study of GI disease
    • Methods to target epithelial cells/GI tissues sRNA or expression vectors or integrative models of gut absorptive & digestive function in humans
    • Communication between basic scientists developing the technology for microbial ecology & clinical scientists who are able to bring them to the pt
    • Genomic & proteomic technologies to identify biomarkers using human intestinal samples
  • 26. Major Challenges to Achieve Goals
    • Drug Development
    • Collaboration between academia & the pharmaceutical & biotech industries
    • High throughput screening of anti-diarrheal drugs that inhibit Cl secretion and/or stimulate Na absorption
    • Collaboration with industry to develop specific microbes (probiotics) or microbial products that stabilize the intestinal mucosal immune system
    • Mutual funding of multicenter trials for therapies of NEC
  • 27. Chapter 11: Diseases of the Liver and Biliary System
      • Chair: Bruce R. Bacon, M.D.
      • Vice-Chair: Maurice Cerulli, M.D.
  • 28. Research Goal 2
    • Liver Cell Injury, Inflammation, Fibrosis and Repair (action plan, chapter 2)
    • Understand the cellular mechanism of liver injury, inflammation, repair and fibrosis and develop effective means for monitory and treating diseases caused by these processes
  • 29. Research Goal 5
    • Viral Hepatitis (action plan, chapter 5)
    • Develop practical, safe, and effective means of prevention, treatment and control of the five forms of viral hepatitis
  • 30. Research Goal 6
    • Viral Hepatitis (action plan, chapter 5)
    • Develop safe, and effective means of prevention, treatment and control of the five forms of viral hepatitis
  • 31. Research Goals 5-8 Objectives
    • Viral Hepatitis (action plan, chapter 5)
    • Develop a vaccine or specific means of prevention of hepatitis C
    • Develop safer & more effective means of treating chronic hepatitis C that can be applied to all categories of patients
  • 32. Research Goals 5-8 Objectives (continued)
    • Viral Hepatitis (action plan, chapter 5)
    • Better understand the structure & replication cycle of HCV for new therapeutic targets, better small molecule therapies
    • Better understand the host & HCV interactions that determine viral clearance vs persistence (poor response in African- Americans)
  • 33. Research Goals 5-8 Objectives (continued)
    • Viral Hepatitis (action plan, chapter 5)
    • Better understanding of the pathogenesis of HBV in all its forms (acute, chronic, active, inactive)
    • Better define the optimal means of treatment of chronic HBV
    • Conduct clinical trials to compare multimodality therapies for HBV
  • 34. Research Goal 9
    • Non-alcoholic Fatty Liver Disease (action plan, chapter 7)
    • Better understanding of the pathogenesis of alcoholic and non-alcoholic liver disease
    • Develop noninvasive means to distinguish steatosis & steatohepatitis
    • Identify & test safe & effective means of treatment of both forms of NAFLD